ArticleCureus2025
The Effectiveness of High-Flow Nasal Cannula in Respiratory Distress in the Pediatric Population of Bundelkhand Region: An Observational Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRespiratory distress is the most frequently encountered cause of admission in the pediatric intensive care unit (PICU) requiring immediate medical attention. Standard oxygen therapy is provided via traditional nasal cannula, oxygen mask, or oxygen hood, whose failure warrants the need for invasive mechanical ventilation. High-flow nasal cannula (HFNC) is increasingly being used as a form of noninvasive respiratory support with fewer side effects and has been shown to reduce the requirement for intubation.
objectivesTo evaluate the effectiveness of HFNC in various indications of respiratory distress and its effect on the length of hospital stay and further complications associated with it. Method: We conducted a prospective observational study at our tertiary PICU between May 2023 and April 2024. Patients aged one month to 18 years with respiratory distress were initially administered standard oxygen therapy escalating to HFNC upon failure. The clinical data and investigations were reviewed.
resultAmong 100 pediatric patients presenting with respiratory distress, 53 were males, with a male-to-female ratio of 1.13:1, and a median age of two years, ranging from three months to 15 years. The most common indication for HFNC was bronchopneumonia (44, 44%), bronchiolitis (31, 31%), asthma (8, 8%), wheeze-associated lower respiratory tract infections (WALRI) (7, 7%), post-extubation (7, 7%), and congenital heart disease with respiratory distress (CHD) without congestive heart failure (CHF) (3, 3%). The overall success rate of HFNC therapy was 87 (87%). The average duration of stay among the success group was 8.69 + -2.26 days, and the failure group was 10.00 + -3.44 days. The average duration of HFNC was markedly longer in the success group (59.39 + -19.84 days) as compared to the failure group (5.69 + -2.02 hours). Factors associated with HFNC failure and the need for invasive ventilation included lower initial and minimum respiratory rate-oxygenation (ROX) indices, as well as higher initial and maximum fraction of inspired oxygen levels. Conclusion: HFNC can be employed as the first line of noninvasive oxygen therapy in cases of respiratory distress, offering an efficient and compassionate alternative that may significantly reduce the incidence of mechanical ventilation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.